• Citer

Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension.

par Vachiery, Jean-Luc ;Hill, Nicholas;Zwicke, Diane;Barst, Robyn J.;Blackburn, Shelmer D.;Naeije, Robert
Référence Chest, 121, 5, page (1561-1565)
Publication Publié, 2002-05

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Continuous i.v. epoprostenol (prostacyclin) therapy improves survival and quality of life in patients with pulmonary arterial hypertension (PAH). i.v. epoprostenol therapy may be limited by serious complications related to the need for an implanted central venous catheter, and its chemical instability and short half-life. Treprostinil is a longer-acting prostacyclin analog, chemically stable, and suitable for continuous subcutaneous administration. We report successful transitioning to subcutaneous treprostinil of patients who presented with life-threatening complications of i.v. epoprostenol delivery.